These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 24399354)

  • 1. Use of fidaxomicin through a nasogastric tube for the treatment of septic shock caused by Clostridium difficile infection in a patient with oral cancer admitted to the Surgical Critical Care Unit.
    Maseda E; Hernandez-Gancedo C; Lopez-Tofiño A; Suarez-de-la Rica A; Garcia-Bujalance S; Gilsanz F
    Rev Esp Quimioter; 2013 Dec; 26(4):375-7. PubMed ID: 24399354
    [No Abstract]   [Full Text] [Related]  

  • 2. Successful treatment of severe Clostridium difficile infection by administration of crushed fidaxomicin via a nasogastric tube in a critically ill patient.
    Arends S; Defosse J; Diaz C; Wappler F; Sakka SG
    Int J Infect Dis; 2017 Feb; 55():27-28. PubMed ID: 28027991
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fidaxomicin (Dificid) for Clostridium difficile infection.
    Med Lett Drugs Ther; 2011 Sep; 53(1373):73-4. PubMed ID: 21921871
    [No Abstract]   [Full Text] [Related]  

  • 4. Successful use of fidaxomicin in recurrent Clostridium difficile infection in a child.
    Smeltzer S; Hassoun A
    J Antimicrob Chemother; 2013 Jul; 68(7):1688-9. PubMed ID: 23463209
    [No Abstract]   [Full Text] [Related]  

  • 5. Treatment of clostridium difficile colitis in the critical care setting.
    Musher DM; Aslam S
    Crit Care Clin; 2008 Apr; 24(2):279-91, viii. PubMed ID: 18361946
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fidaxomicin: the newest addition to the armamentarium against Clostridium difficile infections.
    Lancaster JW; Matthews SJ
    Clin Ther; 2012 Jan; 34(1):1-13. PubMed ID: 22284993
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial.
    Cornely OA; Crook DW; Esposito R; Poirier A; Somero MS; Weiss K; Sears P; Gorbach S;
    Lancet Infect Dis; 2012 Apr; 12(4):281-9. PubMed ID: 22321770
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fidaxomicin "chaser" regimen following vancomycin for patients with multiple Clostridium difficile recurrences.
    Johnson S; Gerding DN
    Clin Infect Dis; 2013 Jan; 56(2):309-10. PubMed ID: 23024296
    [No Abstract]   [Full Text] [Related]  

  • 9. The first Clostridium difficile ribotype 027 strain isolated in Taiwan.
    Lai MJ; Chiueh TS; Huang ZY; Lin JC
    J Formos Med Assoc; 2016 Mar; 115(3):210-2. PubMed ID: 25791539
    [No Abstract]   [Full Text] [Related]  

  • 10. Fidaxomicin: a new macrocyclic, RNA polymerase-inhibiting antibiotic for the treatment of Clostridium difficile infections.
    Poxton IR
    Future Microbiol; 2010 Apr; 5(4):539-48. PubMed ID: 20353295
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antimicrobial activity of LFF571 and three treatment agents against Clostridium difficile isolates collected for a pan-European survey in 2008: clinical and therapeutic implications.
    Debast SB; Bauer MP; Sanders IM; Wilcox MH; Kuijper EJ;
    J Antimicrob Chemother; 2013 Jun; 68(6):1305-11. PubMed ID: 23420839
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fidaxomicin: a novel macrolide antibiotic for Clostridium difficile infection.
    Chahine EB; Sucher AJ; Mantei K
    Consult Pharm; 2014 Sep; 29(9):614-24. PubMed ID: 25203410
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advances in the treatment of Clostridium difficile with fidaxomicin: a narrow spectrum antibiotic.
    Sears P; Ichikawa Y; Ruiz N; Gorbach S
    Ann N Y Acad Sci; 2013 Jul; 1291():33-41. PubMed ID: 23672600
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antibiotics and Clostridium difficile: cause and cure.
    Surawicz CM
    J Clin Gastroenterol; 2007 Jan; 41(1):1-2. PubMed ID: 17198057
    [No Abstract]   [Full Text] [Related]  

  • 15. Is fidaxomicin the drug of choice for treating Clostridium difficile-associated diarrhea in patients with cancer?
    Green MR; Acharya UH; Yeager AM
    J Clin Oncol; 2013 Dec; 31(34):4376-8. PubMed ID: 24166524
    [No Abstract]   [Full Text] [Related]  

  • 16. Fidaxomicin: a review of its use in patients with Clostridium difficile infection.
    Scott LJ
    Drugs; 2013 Oct; 73(15):1733-47. PubMed ID: 24136090
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Clostridium difficile--an increasing problem].
    Anasthesiol Intensivmed Notfallmed Schmerzther; 2013 Jun; 48(6):365. PubMed ID: 23828075
    [No Abstract]   [Full Text] [Related]  

  • 18. [Dificid: fewer recurrences of clostridium difficile].
    Perspect Infirm; 2013; 10(1):60. PubMed ID: 23379054
    [No Abstract]   [Full Text] [Related]  

  • 19. [Clostridium difficile infection. The nosocomial aspect].
    Bucher A; Nordbø G
    Tidsskr Nor Laegeforen; 1995 Apr; 115(11):1361-4. PubMed ID: 7770832
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Resolution of Clostridium difficile-associated diarrhea in patients with cancer treated with fidaxomicin or vancomycin.
    Cornely OA; Miller MA; Fantin B; Mullane K; Kean Y; Gorbach S
    J Clin Oncol; 2013 Jul; 31(19):2493-9. PubMed ID: 23715579
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.